指南与共识儿科与产科急症重症综合管理与镇静镇痛

美国风湿病学会儿童SARS-CoV-2相关多系统炎症综合征与儿童COVID-19高炎症临床指导:第2版

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2.
指南 / 共识 · Arthritis Rheumatol · 2021-02-15
一句话结论美国风湿病学会发布第2版指导,含40条最终声明及MIS-C诊断流程图和初始免疫调节治疗流程图,反映现有证据与专家意见。

该指导由风湿病学、儿科心脏病学、儿科感染病学和儿科重症医学专家组成的特别工作组制定,针对儿童SARS-CoV-2感染后迟发的多系统炎症综合征(MIS-C)以及儿童COVID-19急性感染期高炎症的管理提供建议。工作组基于证据报告形成初步声明,通过改良德尔菲流程(匿名投票和网络研讨会讨论)达成共识,采用9分制评估适当性(中位数1-3为不适当,4-6为不确定,7-9为适当),共识水平根据投票分散程度分为低、中、高。第1版于2020年6月批准,包含40条最终指导声明及MIS-C诊断路径流程图;2020年11月修订新增MIS-C初始免疫调节治疗建议的流程图。该指导反映当前可获得的证据与专家意见,将随新证据出现而修订。

要点

  • 指导涵盖MIS-C(SARS-CoV-2感染后迟发,表现为发热、炎症和多器官功能障碍)及儿童COVID-19急性期高炎症的管理。
  • 第1版于2020年6月批准,含40条最终指导声明及MIS-C诊断路径流程图。
  • 2020年11月修订新增MIS-C初始免疫调节治疗建议的流程图。
  • 共识采用改良德尔菲流程,9分制评估适当性(中位数1-3不适当,4-6不确定,7-9适当),共识水平分低、中、高。
  • 该指导反映现有证据与专家意见,将随证据更新而修订。

适用人群与场景

  • 儿童SARS-CoV-2感染后迟发多系统炎症综合征(MIS-C)患者。
  • 儿童COVID-19急性感染期伴高炎症的患者。

研究设计与关键结果

  • 特别工作组由9名儿科风湿病学家、2名成人风湿病学家、2名儿科心脏病学家、2名儿科感染病学专家和1名儿科重症监护医师组成。
  • 基于证据报告形成初步声明,通过改良德尔菲流程(匿名投票和网络研讨会讨论)达成共识。
  • 采用9分制评估适当性:中位数1-3为不适当,4-6为不确定,7-9为适当;共识水平根据投票分散程度分为低、中、高。
  • 获批指导声明为投票前预设的适当且共识水平为中或高的声明。
  • 第1版于2020年6月批准,包含40条最终指导声明及MIS-C诊断路径流程图。
  • 2020年11月修订,新增MIS-C初始免疫调节治疗建议的流程图。

证据类型、等级与局限

  • 证据类型:指南(临床指导)。
  • 证据基础:现有证据与专家意见相结合。
  • 共识方法:改良德尔菲流程,9分制适当性评分,共识水平分低、中、高。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该指导为MIS-C及儿童COVID-19高炎症的管理提供基于现有证据和专家意见的声明,并附诊断路径和初始免疫调节治疗流程图。
  • 原文未据此给出推荐。

指南或共识出处

  • American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To provide guidance on the management of Multisystem Inflammatory Syndrome in Children (MIS-C), a condition characterized by fever, inflammation, and multiorgan dysfunction that manifests late in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Recommendations are also provided for children with hyperinflammation during coronavirus disease 2019 (COVID-19), the acute, infectious phase of SARS-CoV-2 infection.

METHODS: The Task Force was composed of 9 pediatric rheumatologists and 2 adult rheumatologists, 2 pediatric cardiologists, 2 pediatric infectious disease specialists, and 1 pediatric critical care physician. Preliminary statements addressing clinical questions related to MIS-C and hyperinflammation in COVID-19 were developed based on evidence reports. Consensus was built through a modified Delphi process that involved anonymous voting and webinar discussion. A 9-point scale was used to determine the appropriateness of each statement (median scores of 1-3 for inappropriate, 4-6 for uncertain, and 7-9 for appropriate). Consensus was rated as low, moderate, or high based on dispersion of the votes. Approved guidance statements were those that were classified as appropriate with moderate or high levels of consensus, which were prespecified before voting.

RESULTS: The first version of the guidance was approved in June 2020, and consisted of 40 final guidance statements accompanied by a flow diagram depicting the diagnostic pathway for MIS-C. The document was revised in November 2020, and a new flow diagram with recommendations for initial immunomodulatory treatment of MIS-C was added.

CONCLUSION: Our understanding of SARS-CoV-2-related syndromes in the pediatric population continues to evolve. This guidance document reflects currently available evidence coupled with expert opinion, and will be revised as further evidence becomes available.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

参考来源

  1. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis Rheumatol. 2021. PMID: 33277976. doi:10.1002/art.41616

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。